The efficacy and safety of alectinib in the treatment of ALK+ NSCLC: a systematic review and meta-analysis

BACKGROUND: Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor approved by the US Food and Drug Administration to treat crizotinib-refractory non-small cell lung cancer. We performed this meta-analysis to synthesize the results of different clinical trials to evaluate the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Junsheng, Xia, Zengfei, Zhang, Xiaoli, Chen, Yuqing, Qian, Ruolan, Liu, Sihan, You, Danming, Zhang, Jian, Luo, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840301/
https://www.ncbi.nlm.nih.gov/pubmed/29535535
http://dx.doi.org/10.2147/OTT.S156170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840301/
https://www.ncbi.nlm.nih.gov/pubmed/29535535
http://dx.doi.org/10.2147/OTT.S156170

Ejemplares similares